Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial

By sjmartinez • May 6, 2024

Frantz RP, McLaughlin VV, Sahay S, Escribano Subías P, Zolty RL, Benza RL, Channick RN, Chin KM, Hemnes AR, Howard LS, Sitbon O, Vachiéry JL, Zamanian RT, Cravets M, Roscigno RF, Mottola D, Osterhout R, Bruey JM, Elman E, Tompkins CA, Parsley E, Aranda R, Zisman LS, Ghofrani HA; TORREY Study Investigators. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med. 2024 May 2:S2213-2600(24)00072-9. doi: 10.1016/S2213-2600(24)00072-9. Epub ahead of print. PMID: 38705167.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

The obstacle is the way: Finding a path to hepatitis C elimination

Lo Re V 3rd, Price JC, Schmitt S, Terrault N, Bhattacharya D, Arohnson A. The obstacle is the way: Finding a path to hepatitis C[...]

Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension

Hoeper MM, Ewert R, Jansa P, Sirenko Y, Skride A, Balagtas C, Hackley S, Vogt S, Abreu P, Haughie S, Hassan T, Oudiz RJ. Randomized,[...]

Evolving growth hormone deficiency: proof of concept

Chimatapu SN, Sethuram S, Samuels JG, Klomhaus A, Mintz C, Savage MO, Rapaport R. Evolving growth hormone deficiency: proof of concept. Front Endocrinol (Lausanne). 2024[...]